Relative in Vitro Efficacy of the Phosphate Binders Lanthanum Carbonate and Sevelamer Hydrochloride

Autissier, Valerie; Damment, Stephen J.P.; Henderson, Richard A.

doi:10.1002/jps.20956

Cited by 65 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the reported tablet burden of seven (800 mg) to 17 (403 mg) pills per day for sevelamer hydrochloride and eight to 12 pills per day for calcium-based agents (14 -16), the tablet burden with the reformulated preparation is substantially lower. The lower tablet burden associated with lanthanum carbonate compared with other oral phosphate binder medications (17) may be indicative, at least in part, of the greater relative potency of lanthanum carbonate in in vitro studies (18). Reduction in daily phosphate-binder tablet burden and improved satisfaction with higher strength lanthanum carbonate may help improve patient adherence, with a potentially positive impact on clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Mehrotra

Martin

Fishbane

et al. 2008

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Results: At the end of week 4, 54% of patients achieved serum phosphorus control at dosages <3000 mg/d administered as one tablet per meal. Among patients who entered cohort B, control rates of 25, 38, and 32% for patients who were randomly assigned to 3000, 3750, or 4500 mg/d lanthanum carbonate, respectively, were achieved, with no increase in adverse events. Patients and physicians reported significantly higher levels of satisfaction with reformulated lanthanum carbonate compared with previous phosphate binders, partly because of reduced tablet burden with higher dosage strengths. Physicians and patients also expressed a preference for lanthanum carbonate over previous medication.Conclusions: Reformulated lanthanum carbonate is an effective phosphate binder that may reduce daily tablet burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Mehrotra

Martin

Fishbane

et al. 2008

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Clinical trials with a ‘treat to target’ design have shown that lanthanum carbonate has similar efficacy to alternative phosphate-binder therapy (which has included sevelamer hydrochloride) [7, 8], whereas in vitrostudies have shown that lanthanum carbonate has a higher binding affinity and specificity for phosphate when compared both with calcium-based binders and sevelamer hydrochloride [2, 3]. Thus, lanthanum carbonate has the potential to reduce tablet burden in patients with hyperphosphatemia.…”

Section: Discussionmentioning

confidence: 99%

“…Preclinical studies have shown that lanthanum binds phosphate equally well at all relevant pH levels throughout the gastrointestinal tract [2, 3]. In short-term, placebo-controlled clinical trials, lanthanum carbonate was significantly more effective than placebo in reducing serum phosphate levels, with a safety profile similar to that of placebo and a rapid onset of action within 1–2 weeks [4,5,6].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Hutchison

Barnett²,

Krause³

et al. 2008

Nephron Clin Pract

104

View full text Add to dashboard Cite

Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy. Methods: Patients from four previous trials entered this study. Results: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium × phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system. Conclusions: LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs.

show abstract

“…Thus, in this study, we evaluated the phosphorus absorption-reducing efficacy between JTT-751 and the existing phosphate binders (lanthanum carbonate and calcium carbonate). Although in vitro phosphate-binding studies are one of the possible tools for an estimating binder's phosphate-binding activity in clinical use, 14,18 we selected an in vivo evaluation because it is under more physiological conditions, and JTT-751 is a compound which includes citrate, which has a dissolving effect on ferric phosphate especially in in vitro closed conditions. Although we divided it into two experiments by similar protocols due to our capacity of carrying out a single experiment, the amounts of urinary phosphorus excretion in the control groups were almost same between two experiments in this study.…”

Section: Discussionmentioning

confidence: 99%

The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

et al. 2014

View full text Add to dashboard Cite

Hyperphosphatemia is a risk factor for arterial calcification contributing to the highcardiovascular mortality in patients with chronic kidney disease (CKD). Ferric citrate hydrate (JTT-751) is being developed as a treatment for hyperphosphatemia with chronic renal failure and has shown a serum phosphorus-lowering effect in CKD patients. In this study, we evaluated the combination effect of JTT-751 with the phosphorus absorption-reducing effect of calcium carbonate and compared phosphorus absorption-reducing efficacy between three phosphate binders including JTT-751. Normal rats were fed a diet containing either 1% calcium carbonate, 1% JTT-751 or 1% JTT-751 with 1% calcium carbonate, for 7 days. Both 1% calcium carbonate and 1% JTT-751 alone reduced urinary phosphorus excretion, and the combined treatment reduced it more than each single-treatment, without clearly influencing calcium or iron-metabolism. Next, normal rats were fed a diet containing either 0.3, 1 and 3% lanthanum carbonate or 2.3% JTT-751, for 7 days. Either 3% lanthanum carbonate or 2.3% JTT-751 reduced urinary phosphorus excretion. Finally, we compared the reduced amount of urinary phosphorus excretion per dose of compound, of which JTT-751 is comparable to that of calcium carbonate and is greater than that of the lanthanum carbonate. In conclusion, JTT-751 showed an additive effect on the phosphorus absorptionreducing effect of calcium carbonate without influencing calcium-and iron-metabolism, and had a phosphorus absorption-reducing efficacy comparable to or greater than other existing phosphate binders.

show abstract

Relative in Vitro Efficacy of the Phosphate Binders Lanthanum Carbonate and Sevelamer Hydrochloride

Cited by 65 publications

References 27 publications

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

Contact Info

Product

Resources

About